Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Efgartigimod for Myasthenia Gravis
Recruiting2 awardsPhase 3
Gatineau, Quebec
This trial is a 26-week study where a new therapy called efgartigimod will be used instead of IVIG for a condition called myasthenia gravis. Patients will be
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service